Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran.
The aim of the study was to evaluate the efficacy and safety of interferon beta-1a (Avonex) and intravenous immunoglobulin (IVIG) in clinical practice for the treatment of relapsing-remitting multiple sclerosis. Avonex is the most common disease-modifying therapy used in Iran due to its ease of administration. IVIG is also frequently used due to its alleged effectiveness and fewer side effects. Eighty patients were selected and prospectively monitored according to a predefined protocol. They were then randomized to receive either weekly intramuscular injections of Avonex or 0.4 g/kg monthly IVIG in a single blind fashion and following an attack of exacerbation which was treated with steroids. Basal relapse rate and Expanded Disability Status Scale (EDSS) were similar in both groups of patients (p > 0.4). Seventy-two patients remained in the study. The annual relapse rate consistently decreased from 0.95 +/- 0.41 to 0.60 +/- 0.67 (approximately 32%, p < 0.001) for 34 patients treated with Avonex and from 1.05 +/- 0.34 to 0.55 +/- 0.46 for 38 patients in the IVIG group (approximately 47%, p < 0.001). EDSS decreased by 0.4 units in IVIG-treated patients (p < 0.001) and remained stable (0.2 < p < 0.3) in the Avonex arm. This study confirms the relative efficacy of both treatments with better safety profile for IVIG in the studied Iranian population. However, the results are very preliminary ones, due to limited numbers of patients and only 12 months of treatment.
Kalanie
Hossein
H
Shahid Beheshtie University of Medical Sciences, Department of Neurology, Loghman Hospital, Tehran, Iran. Kalanie@afranet.com
Gharagozli
Kurosh
K
Hemmatie
Abolfazl
A
Ghorbanie
Mehdie
M
Kalanie
Amir Reza
AR
D000293:Adolescent; D000328:Adult; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D016899:Interferon-beta / Q000627:therapeutic use*; D007492:Iran / Q000453:epidemiology; D008297:Male; D009103:Multiple Sclerosis / Q000628:therapy*; D009460:Neurologic Examination; D012189:Retrospective Studies; D016037:Single-Blind Method; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D016899:Interferon-beta